| INTRODUCTION
Evidence for the cognitive impact of cancer and cancer treatments has grown over the last 20 years based on studies ranging from prospective assessments with neuropsychological tests, imaging, and biomarkers to animal model studies. 1 Research examining the cognitive impact of brain tumors and treatments that directly affect the brain (cranial surgery and radiation therapy) has a long history. 2 Additionally, there is a substantial literature examining cognitive deficits in children treated for cancer 3 and a growing literature on cognitive functioning in adult survivors of childhood cancers. 4 However, evidence for cancer associated cognitive decline (CACD) for the common non-CNS cancers in adults (breast, colon, lymphoma, and prostate) has significantly broadened the scope of the field. Research has examined cognitive change across a variety of cancer types (primarily, breast cancer, but increasingly in colon, prostate, and hematological cancers) and across a variety of treatments (standard and high dose chemotherapy with stem cell transplant, endocrine / hormone ablation therapies, and local radiation). Cancer is frequently treated with multiple modalities, which complicates the study of CACD and the identification of the components of treatment responsible for cognitive change. Treatment for many cancers may consist of a combination of surgical resection, systemic chemotherapy, and local radiation therapy, with additional treatments for specific cancers (eg, endocrine therapy for breast cancer and hormone ablation for prostate cancer), and emerging evidence suggests that all of these treatments can potentially impact cognitive function. 5 Therefore, even though many researchers have assumed that they are studying the cognitive effects of chemotherapy ("chemobrain"), in reality, most of the research has examined the cognitive impact of the entire package of treatment exposures. The goals of this manuscript are to describe the conceptual and methodological challenges and emerging issues in the study of cognition and cancer.
| MULTIPLE DETERMINANTS OF COGNITIVE DECLINE IN CANCER PATIENTS
Initially, researchers in this area conceptualized the problem of chemotherapy-induced cognitive decline from a pharmacotoxicology perspective, ie, patients diagnosed with cancer would have normal cognitive functioning prior to treatment that would be adversely affected by exposure to certain chemotherapeutic agents. However, several findings have challenged this conceptualization including the identification of (1) pretreatment cognitive problems in a subset of patients, (2) evidence that multiple components of treatment potentially affect cognitive function, and (3) multiple risk factors including age, cognitive reserve, genetic polymorphisms (APOE, COMT, and BDNF), pathologic tumor markers, and comorbidities. Additionally, although not well studied in this area, research from other areas suggests that the biological impact of stress and low socioeconomic status and racial / ethnic factors may also influence risk for cognitive decline in cancer patients. 5 Figure 1 provides a conceptual model that outlines the multiple factors that may contribute to post-treatment cognitive decline. One implication of this model is that sociodemographic, life style, psychological, physiological, and genetic factors as well as the "wear and tear" on the biological system related to coping with the demands and stress of life (allostatic load) 6 may be as important in determining the risk of post-treatment cognitive decline as the specific treatments received.
Further, it is possible that particular constellations of risk factors may make one patient more vulnerable to the side effects associated with chemotherapy, whereas another set of risk factors may make another patient more sensitive to the side effects of endocrine therapy.
| AGING, COGNITION, AND CANCER
Life expectancy has increased dramatically over the last 100 years. 7 As a result, older adults make up an increasingly large proportion of the total population. At the turn of the century, 13% of the population was aged 65 and over, amounting to around 35 million individuals;
by 2050, this number is projected to double to 70 million individuals, which will represent approximately 20% of the US population. 8 As cancer is a disease of aging, 9 the changing demographics of the nation will result in an increase in the number of individuals diagnosed with and surviving cancer. Indeed, there is a projected 67% increase in cancer incidence in patients aged 65 and older from 2010 to 2030, 10 and older adults will make up 60% of the cancer survivors in the USA.
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Most of the research on CRCD has been done in patients with breast cancer and breast cancer survivors comprise nearly 25% of all survivors over the age of 60. Although increasing evidence suggests that exposure to systematic breast cancer treatments (chemotherapy and endocrine therapy) may be associated with long-term cognitive deficits in a subgroup of cancer survivors, most studies have been conducted with younger cancer patients (mean age [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] . 12 Hence, little is known about the long-term impact of adjuvant treatment on cognitive function, or the risk factors for treatment-driven cognitive decline. Therefore, a critical gap in knowledge relates to the impact of cancer and cancer treatment on cognitive functioning in older patients with breast cancer.
It is especially important to study the association between cancer therapy and cognitive decline in older adults because among the side effects that older patients fear most from cancer therapy is the prospect of diminished cognition. 13 In a recent study conducted by 23 and is marked by a decrease in cerebral blood flow, white matter atrophy, and impairments in processing speed, sequence-learning ability, short-term memory, and increased reaction time, 24 impairments frequently seen in cancer survivors.
Of the few studies on the association between cancer therapy and cognition that focused on older patients, results are somewhat inconsistent. In a longitudinal study of 1280 breast cancer survivors, Mandelblatt et al 25 found that the majority of older survivors selfreported good cognitive function while only a small subset of older survivors exposed to chemotherapy self-reported accelerated cognitive decline. Heck and colleagues performed an analysis using the Surveillance, Epidemiology, and End Results-Medicare database and found a long-term association between a diagnosis of dementia and chemotherapy in women over age 65, 26 and Schilder et al 27 found that 1 year of tamoxifen was associated with worsening cognitive function with patients age ≤ 65 performing worse than healthy controls on executive functioning and those > age 65 performing worse than healthy controls on verbal memory and information processing speed. Minisini et al 28 prospectively measured cognitive function in older patients with breast cancer who received no adjuvant treatment or were treated with chemotherapy with or without endocrine therapy and found that more patients in the chemotherapy group showed worsening memory skills, and more patients in the endocrine therapy and chemotherapy group experienced reduction in attention scores. 28 Other studies have raised concerns about the short and long-term impact of chemotherapy in older adults with breast cancer. On the other hand, some studies found no association between cancer therapy and self-reported cognitive function, 33 or found inconsistency between patient-reported and demonstrated, objective evidence of cognitive decline. In a pilot longitudinal study of the cognitive effects of chemotherapy in older (>65) patients with breast cancer, 50% of patients reported decline in cognitive functioning post-chemotherapy and 25% demonstrated evidence of a decline in performance from pre-treatment to post-treatment on neuropsychological tests. 30, 31, 34 In another study, 35 Animal studies have also demonstrated that the administration of cyclophosphamide and doxorubicin to rats increases activation of markers of aging and stress (Erk1/2 and AKT). 37 Consequently, researchers have speculated that cancer treatments may affect specific brain regions and the biology of aging, including cognitive aging. 1, 38 Therefore, as our population ages, a critical research question is whether the diagnosis of cancer and exposure to cancer treatments has an initial post-treatment effect on certain domains of cognitive function and regions of the brain followed by age-associated cognitive decline that parallels those of older adults with no cancer history 
| Compensatory activation
Imaging research has demonstrated that, in the face of alterations to structure or function, the brain has the capacity for compensatory activation that allows for recruitment of alternate brain regions in order to maintain cognitive performance. Compensatory activation has been observed in normal aging 40 and in cancer survivors. 41 Cancer survivors frequently report that cognitive tasks require more effort and are more easily disrupted in the real world of distractions, stress, etc. 42 However, standard neuropsychological tests are administered in an environment designed to minimize distraction and maximize performance. Therefore, survivors' perception of cognitive problems in their day-to-day lives may well be accurate; however, performance is maintained in the neuropsychological testing setting which likely maximizes compensatory mechanisms.
| Memory versus attention
Another explanation for this discrepancy is related to survivors' experience of cognitive change and the actual cognitive processes that are altered by cancer treatments. These findings suggest that initial attention, registration, and encoding of information may be altered in survivors, and argue for a greater emphasis on attentional processes and sub-processes. Recent studies have found increased variability of attention across longer go/no-go tasks, with particularly variable attention in low-challenge conditions, and increasing variability in the latter portions of the task both before 45 and following treatment. 46 This suggests that survivors tended to lose focus throughout the task, particularly in relatively unstimulating conditions, as well as in later phases of the task.
At this point, the precise mechanism(s) for learning difficulties have not been defined; however, we and others have proposed that changes in attentional processes both pre-attentive and volitional (orienting, shifting, disengaging, and inhibiting attention) interfere with efficient and effective encoding of information in memory. 
| Statistical issues
The lack of correlation between self-report of cognitive problems and performance on neuropsychological tests may also be related to limitations of statistical approaches used to evaluate this association.
Conventional statistical methods rely on aggregating item responses into total scores or sub-domains and submitting these to traditional, correlation-based analyses. A recent study has identified significant associations between self-reported dysfunction and traditional neuropsychological measures using latent regression Rasch modeling. 50 The latent Rasch approach: (1) directly models individual, item-level, cognitive symptom ratings, whereas the conventional approach aggregates over symptom ratings to form subscale or global scores, obscuring specific patterns of symptoms and (2) weights the endorsement of rare symptoms more highly than commonly reported symptoms, whereas the conventional approach weights all symptoms identically. Use of the Rasch approach revealed that changes in objective performance from pre-treatment to post-treatment predicted self-report of cognitive problems, whereas traditional correlations were low or non-significant. 50 Consistent with the proposed role of attention, self-reported memory problems correlated with performance on measures of attention and processing speed rather than measures of memory. Transcranial direct current stimulation (tDCS), used in other disorders, may also enhance the impact of approaches like perceptual training. tDCS delivers a minimal electric current by means of electrodes placed on the scalp and exerts its effect by lowering the threshold at which action potentials are generated. 52 As such, combining tDCS with cognitive training may "open windows of neuroplasticity" in effected areas that are supportive of a given cognitive task, eg attentional function. 6 6 | EMERGING ISSUES 
| Treatment implications

| Tipping point
Although expansion of the conceptual model may be a more accurate portrayal of the multiple factors that can lead to the experience of cognitive decline in cancer survivors, it makes research in the area much more complicated. If post-treatment cognitive deficits are determined by a complex interaction of specific impacts of cancer treatments on brain structure and function, innate (eg, genetic) and acquired risk factors, and aging, the determination of specific mechanisms of CACD becomes a significant challenge. However, research related to the concept of tipping points in complex systems may be relevant. 55, 56 Many complex systems, ranging from climate change, to financial markets, to social networks, have tipping points at which there is an abrupt change from one state to another. Prediction of these transitions is difficult because of the complexity of the system and because the system may show little evidence of change prior to the transition.
However, early-warning signs for critical transitions have been identified which relate to the phenomenon in dynamic systems theory known as "critical slowing down". 55, 56 Characteristics of critical slowing include (1) overall slowing of the system; and either, (2) increased autocorrelation (ie, because of slowing of the system, the rate of change decreases, hence the state of the system at any given time is more similar to past states); or (3) increased variability. Examination of cognitive performance seen in cancer patients has demonstrated (1) slowing of processing speed 57 ; (2) decreased ability to benefit from practice (performance from Time 1 to Time 2 remains similar; which may be a sign of higher autocorrelation) 58 ; and (3) increased intra-individual variability on reaction time tasks seen both before 45 and following treatment. 46 At least 2 questions for future research emerge from this conceptualization. First does "critical slowing" prior to treatment, represented by slowed processing speed, inability to benefit from practice, and/or increased variability in reaction time, predict vulnerability to post-treatment cognitive decline? Second, neuropsychology researchers commonly dichotomize survivors into impaired or not impaired. However, another hypothesis is that all patients are affected at the same level by a given treatment in terms of brain structure and function, but only a subgroup reaches a tipping point where the cognitive system shifts to a new state that is no longer sufficient to maintain pre-diagnosis task performance and cognitive deficits are measurable.
Future research is necessary to determine the validity of these hypotheses and the utility of this conceptualization. information is needed to more fully understand how cancer and cancer therapy may affect both physiological aging and cognitive aging, and how this impact can vary based on patients' age at treatment, comorbid conditions, and overall health status. We suggest that future research needs to address the complex, interacting factors that influence cognitive function in cancer survivors, examine both the direct effects of cancer treatments on brain structure and function and the impact on cancer treatments on the biology of aging, and address conceptual and methodological issues that may explain inconsistencies in research findings and limit progress in the field.
